Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
RHHBY - ROCHE HOLDINGS AG SPN ADR EACH
Market Cap 249.67B P/E 17.09 EPS this Y 6.60% Ern Qtrly Grth -12.30%
Income 10.62B Forward P/E - EPS next Y 10.20% 50D Avg Chg -2.00%
Sales 60.58B PEG 3.32 EPS past 5Y 4.84% 200D Avg Chg -2.00%
Dividend 25.00% Price/Book 8.75 EPS next 5Y 4.30% 52W High Chg -12.00%
Recommedations 2.00 Quick Ratio 0.80 Shares Outstanding 5.52B 52W Low Chg 10.00%
Insider Own - ROA 12.49% Shares Float 726.97M Beta 0.15
Inst Own 0.28% ROE 36.36% Shares Shorted/Prior -/- Price 38.29
Gross Margin 74.54% Profit Margin 17.53% Avg. Volume 1,977,061 Target Price 44.34
Oper. Margin 35.27% Earnings Date Jul 25 Volume 761,977 Change -0.03%
Healthcare | Drug Manufacturers - General | Switzerland
About ROCHE HOLDINGS AG SPN ADR EACH

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

ROCHE HOLDINGS AG SPN ADR EACH News
12/19/24 Roche's Prasinezumab Misses Goal in Parkinson's Disease Study
12/19/24 Roche’s Parkinson’s Drug Candidate Misses Key Goal in Mid-Stage Study
12/19/24 Prothena’s Parkinson’s study fails primary endpoint despite some success
12/19/24 Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease
12/19/24 Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease
12/18/24 Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution
12/16/24 Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
12/14/24 Roche Vabysmo PFS approved in EU for three retinal conditions
12/13/24 Roche’s cobas 6800/8800 systems receive CE certification
12/13/24 Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge
12/13/24 AbbVie to acquire Roche spinout Nimble in immune drug deal
12/13/24 Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
12/13/24 Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities
12/10/24 New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma
12/09/24 New and Updated Data for Genentech’s Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma
12/09/24 Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash
12/08/24 Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
12/08/24 Five-Year Results Confirm Genentech’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma
12/06/24 Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ
12/05/24 FDA Accepts Roche's Columvi sBLA for Expanded Use in Lymphoma